Pancreatic Cancer Genetics
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to determine the frequency of the three most common BRCA1 and BRCA2 genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
| Condition |
|---|
|
Pancreatic Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients |
- Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients [ Time Frame: 1 year ] [ Designated as safety issue: No ]The primary aim of this study is to determine the combined frequency of BRCA1 (185delAG, 5382insC) and BRCA2(6174delT) mutations in Ashkenazi Jewish pancreatic cancer patients.
- Individual Frequency of Three Mutations [ Time Frame: 1 year ] [ Designated as safety issue: No ]Individual frequency of these mutations three mutations BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) mutations.
- Frequency of disease modifying mutations [ Time Frame: 1 year ] [ Designated as safety issue: No ]Determine the frequency of disease modifying mutations such as MSH2 A636P, APC I1307K, P53, R72P, CHEK2 S428F, RAD51 G135C and MTHFR V222A.
- Other Variables in Patients with Positive Mutations [ Time Frame: 1 year ] [ Designated as safety issue: No ]Study death from any cause, disease-free survival, stage of disease at time of presentation (Pan-In Stage 1-3 and tumor stages), differences in tissue pathology, risk factors, treatment decisions, and development of another malignancy in patients with positive mutations.
Biospecimen Retention: Samples With DNA
- Peripheral Blood Specimens: Three tubes of blood will be collected from each study participant. Two tubes will be EDTA-whole blood and one tube will be serum. Each tube will contain ~4-5 ml. A portion of the blood will be utilized to extract white blood cells that will be immortalized by EBV infection.
- Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or elsewhere, will be requested after obtaining consent for study participation.
- Fresh Tissue Collection: At the time of surgery for tumor resection, tumor and adjacent normal tissue will be requested from the Pathology Department. At the time of endoscopy, aspirated fluid or biopsied tissue will be requested. No additional tissue will be resected beyond that required for surgical or endoscopic management.
- Genetic Testing: All genetic testing will be performed in a research laboratory. Test results from research laboratories will not be disclosed to patients.
| Estimated Enrollment: | 325 |
| Study Start Date: | May 2007 |
| Estimated Study Completion Date: | August 2012 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
Pancreatic cancer is the fourth leading cause of death from malignancy in the United States. Up to 15% of pancreatic cancers have a hereditary component. Several gene mutations and cancer syndromes have been identified that are frequently found in greater frequency in individuals with pancreatic cancer, including the breast ovary cancer syndrome (BRCA1/BRCA2 mutations). No studies adequately describe the epidemiology of inherited pancreatic cancer and genetic risk factors that may modify the penetrance of BRCA1/BRCA2 mutations. The primary aim of this study is to determine the frequency of BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT) mutations in Ashkenazi Jewish pancreatic cancer patients. Secondary endpoints will include determining the individual frequency of these mutations and other disease-modifying mutations, death from any cause, disease-free survival, and stage of disease at time of presentation, differences in tissue pathology, risk factors, treatment decisions and development of metachronous malignancies. We plan to study 385 patients, which will enable the true frequency of the mutation to be estimated. Although the impact of BRCA1/BRCA2 mutations will be initially studied in the Ashkenazi population, these data will be widely applicable to other pancreatic cancer patients carrying BRCA1/BRCA2 mutations. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may allow early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study subjects will be pancreatic cancer patients at CUMC who are of Ashkenazi Jewish descent.
Inclusion Criteria:
- Patients diagnosed with pancreatic cancer.
- Patients are of Ashkenazi Jewish descent.
- Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154).
Exclusion Criteria:
- Inability to provide informed consent.
- Under the age of 18 years old.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01102569
| Contact: Wendy K Chung, MD | wkc15@columbia.edu | ||
| Contact: Ashley Dikos | ajd2147@columbia.edu |
| United States, New York | |
| Columbia University Medical Center | Recruiting |
| New York, New York, United States, 10032 | |
| Contact: Wendy K Chung, MD wkc15@columbia.edu | |
| Contact: Ashley Dikos ajd2147@columbia.edu | |
| Principal Investigator: Wendy K Chung, MD | |
| Principal Investigator: | Wendy K Chung, MD | Columbia University |
More Information
No publications provided
| Responsible Party: | Wendy K. Chung, Assistant Professor of Pediatrics, Molecular Genetics, Columbia University |
| ClinicalTrials.gov Identifier: | NCT01102569 History of Changes |
| Other Study ID Numbers: | AAAC6344, AAAC-6344(Y3M00) |
| Study First Received: | April 12, 2010 |
| Last Updated: | July 2, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Columbia University:
|
Hereditary pancreatic cancer Breast and Ovarian Cancer Syndrome BRCA1/2 Ashkenazi Jewish patients |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms |
Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases |
ClinicalTrials.gov processed this record on March 03, 2015